Peter Wehrwein, Managing Editor

Peter Wehrwein, Managing Editor

Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.

Articles by Peter Wehrwein, Managing Editor

Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific officer says the complexity of Duchenne muscular dystrophy may ultimately mean that a number of different therapies will be used together,